BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biocodex readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biocodex's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06465472-8866@assetmemo.bio
DTSTAMP:20261121T005847Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Stiripentol: Phase 3 readout est. (NCT06465472)
DESCRIPTION:Stiripentol\, phase 3\, Primary Hyperoxaluria Type 1.\nStudy: E
 valuation of the Efficacy and Safety of Stiripentol in Patients 6 Years an
 d Older With Primary Hyperoxaluria Type 1\, 2 or 3\nEstimated primary comp
 letion: August 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 stiripentol#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06465472
URL:https://assetmemo.bio/drug/stiripentol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
